Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vtv Theraptcs Cl A (VTVT)

Vtv Theraptcs Cl A (VTVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vtv Theraptcs Cl A 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 USA

www.vtvtherapeutics.com Employees: 26 P: 336-841-0300 F: 866-306-5107

Sector:

Medical

Description:

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.

Key Statistics

Overview:

Market Capitalization, $K 141,660
Enterprise Value, $K 52,730
Shares Outstanding, K 3,938
Float, K 3,773
% Float 95.80%
Short Interest, K 57
Short Float 1.45%
Days to Cover 2.27
Short Volume Ratio 0.58
% of Insider Shareholders 4.20%
% of Institutional Shareholders 17.51%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -26,970 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -7,140 K
EBIT, $ -32,800 K
EBITDA, $ -32,780 K

Growth:

1-Year Return 104.49%
3-Year Return 13.47%
5-Year Return -65.55%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 52.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.58 on 03/10/26
Next Earnings Date 05/21/26
Earnings Per Share ttm -3.35
EPS Growth vs. Prev Qtr 46.30%
EPS Growth vs. Prev Year -5.45%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-40 on 11/21/23

VTVT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -73.76%
Return-on-Assets % -43.53%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.22
Book Value/Share 16.36
Interest Coverage -3,107.00
60-Month Beta 0.44
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.